<DOC>
	<DOCNO>NCT00271024</DOCNO>
	<brief_summary>The purpose propose study conduct randomize , double-blind clinical trial compare adjunct treatment 50 mg oral naltrexone vs. placebo conjunction standard smoke cessation treatment nicotine patch counseling . Hypotheses : 1 . Naltrexone improve smoke cessation quit rate , measured end active treatment ( 3 month ) long term follow ( 1 year ) . 2 . Weight smoking-related variable ( i.e. , less weight gain , well reduce crave withdrawal ) important factor naltrexone improve smoke cessation outcome . 3 . These effect predict strong woman compare men .</brief_summary>
	<brief_title>Efficacy Naltrexone Women 's Smoking Cessation</brief_title>
	<detailed_description>Although woman may particularly susceptible damage effect chronic cigarette smoking , evidence indicates may difficulty maintain smoke cessation men . Given woman 's reduce response nicotine replacement traditional treatment habitual cigarette smoking , target pharmacotherapy intervention strategy may necessary improve quit rate . Preliminary data group others indicate opioid antagonist naltrexone may effective adjunctive pharmacotherapy approach female smoker . The purpose propose study conduct randomize clinical trial compare adjunct treatment 50 mg oral naltrexone vs. placebo conjunction standard smoke cessation treatment nicotine patch counseling . Participants ( N=324 ) randomize receive either naltrexone placebo start one week prior quit date ( 25 mg three day ; 50 mg thereafter ) continue 12 week quit date . The effect naltrexone evaluate pre-quit date period , initial smoking cessation , relapse prevention , one year follow-up . It hypothesize sex moderate effect naltrexone outcome , naltrexone improve prolonged abstinence quit rate woman men . The secondary goal elucidate mechanism underlie woman 's treatment response naltrexone . Weight ( relative weight gain weight concern ) smoking-related variable ( reduce cigarette pleasure , taste , crave relief negative withdrawal affect ) may important factor naltrexone improve quit rate woman . Medication compliance , psychosocial stress level naltrexone 's metabolite , 6-B-naltrexol , also examine . In sum , propose clinical trial provide comprehensive study sex difference response adjunct treatment naltrexone smoking cessation . Given public health concern significant health consequence woman 's continued high rate smoke , propose study may provide important information novel treatment strategy target endogenous opioid system selectively aid woman 's smoke cessation .</detailed_description>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Age 1865 , male female 2 . Cigarette smoker least 15 40 cigarette daily least two year 3 . Current diagnosis DSMIV Nicotine Dependence , base SCID interview 4 . Relatively healthy , medical psychiatric condition would adversely interact study parameter ( see exclusion criterion specific detail ) 5 . Desire quit smoking ( selfreport rating interest quit least 7 10point scale ) 6 . NicometerÂ® cotinine level baseline least 5 6point scale 7 . Reports quit smoking past three month one week duration 8 . Agrees attend behavioral counseling session complete study measure 9 . Has stable residence telephone provide name outside household collateral family member close friend 1 . Substance Dependence last one year ( DSMIV Nicotine Dependence ) history Opioid Dependence ( lifetime ) 2 . Major psychiatric disorder last one year , include Axis I disorder history moderate/severe Axis II Disorder , Bipolar Disorder Psychotic Disorder , base SCID interview standard cutoff threshold screen questionnaire 3 . Past current medical disorder ( cardiovascular , hepatic , neurological , endocrine , etc . ) may adversely interact study measure 4 . Clinically significant lab test abnormality , positive urine toxicology , positive pregnancy test 5 . Currently pregnant , plan become pregnant , lack effective birth control next three month , and/or currently lactate , plan breastfeed next three month 6 . History adverse reaction opioid antagonist nicotine replacement treatment 7 . Use medication may adversely interact study measure ( antidepressant , phenothiazine , benzodiazepine , etc . ) ; recent regular use opioid medication 8 . Unwillingness attend smoke cessation treatment session , take nicotine patch , randomize medication placebo condition , available followup assessment 9 . Unwillingness agree DNA analysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Smoking Cessation</keyword>
</DOC>